



**RODRIGO NEL CORDOBA ROJAS**

MD PSYCHIATRIST

PROFESSION MD, PSYCHIATRIST

Address: Street 173 A #65-85 Bogotá - Colombia

Phone: 57 1 390 71 22. Mobile: 315 3368990 Fax: 57 1 390 71 24

e-Mail: [rodrigo.cordoba@grupocisne.org](mailto:rodrigo.cordoba@grupocisne.org); [rodrinel@yahoo.com](mailto:rodrinel@yahoo.com)

**EDUCATION AND TRAINING:**

Postgraduate:

Institution: Universidad Nuestra Señora Del Rosario

Course and title obtained: University Teaching Specialization – Specialist in University Teaching

Period: 1994-1996

City: Bogotá.

Institution: Universidad Nuestra Señora Del Rosario

Course and title obtained: Psychiatry Residency - Psychiatrist

Period: 1984-1987

City: Bogotá.

University:

Institution: Universidad Nuestra Señora Del Rosario

Course and title obtained: Medicine – M.D.

Period: 1976-1983

City: Bogotá.

High School:

Institution: Colegio José Max León

Course and title obtained: High School – High School Degree

Period: 1962-1974

City: Bogotá

**EXPERIENCIA PROFESIONAL:**

Institution: Centro de Investigaciones del Sistema Nervioso GRUPO CISNE LTDA.

Position: Founder, General Director.

Dates: Jan 2002 – Current.

City: Bogotá – Colombia.

Institution: Universidad del Rosario.

Position: Associate Professor

Date: 1991 – Current.

City: Bogotá – Colombia.

Institution: CENTRO CAMPO ABIERTO-ORGANIZACIÓN SANITAS INTERNACIONAL

Position: General Director, Psychiatrist.



Date: jan 2008 – Current.  
City: Bogotá – Colombia.

Institution: DESARROLLO INTEGRAL ADVANCE  
Position: General Director, Psychiatrist.  
Date: 2000 – 2010.  
City: Bogotá – Colombia.

Institution: SERVIPSA-SERVICIOS PSIQUIÁTRICOS S.A UNIDAD DE INTERVENCIÓN EN CRISIS UIC.  
Position: General Director, Psychiatrist.  
Date: Oct 2003 – Nov 2007.  
City: Bogotá – Colombia.

Institution: ORDEN HOSPITALARIA DE SAN JUAN DE DIOS  
Position: Country Mental Health Advisor.  
Date: 1991 – 2004  
City: Bogotá – Colombia.

Institution: CLÍNICA DE NUESTRA SEÑORA DE LA PAZ  
Position: Medical Education & Research Director, Psychiatrist.  
Date: Jul 1988 – Aug 2004.  
City: Bogotá – Colombia.

Institution: ESCUELA DE MEDICINA JUAN N.CORPAS  
Position: Residency Program Director. Residency Professor.  
Date: 1990 - Jun 2004  
City: Bogotá – Colombia.

Institution: FUNDACIÓN UNIVERSITARIA SAN MARTIN  
Position: Adjunct Professor  
Date: 2002 - 2013  
City: Bogotá – Colombia.

Institution: FUNDACIÓN UNIVERSITARIA MANUELA BELTRAN  
Position: Adjunct Professor  
Date: 2002 - 2013  
City: Bogotá – Colombia.

Institution: Ministry of Justice  
Position: Psychiatrist  
Date: 1989 - 1996  
City: Bogotá – Colombia.



**PREVIOUS PARTICIPATION IN CLINICAL TRIALS:**

Study	Phase	Indication	Start Date	Closure Date	Role	Scales
Protocol ZIP-NY-97-019: Double Blind Treatment 12 weeks Zeldox vs Olanzapine	III	SCHIZOPHRENIA with DEPRESSIVE SYMPTOMS	01-jul-99	01-dec-00	Principal Investigator	Paraclinics folow up
Protocol ZIP-NY-98-035: Open label Treatment with Ziprasidona	III	SCHIZOPHRENIA	01-jan-00	Aug-01	Principal Investigator	Paraclinics folow up
Protocol F1J-MC-HMAU.8: Open Treatment with Clorhidrato of Duloxetine	IV	MAJOR DEPRESSION	01-feb-00	jul-02	Principal Investigator	CGI-S, PGI-S, BPI, SF-MPQ, HAMD 17, EQ-5D, SF-36
Protocol PRI/TOP-INT-50: Double Blind, controlled with placebo and active comparator. Acute phase and extensión with a new antipsychotic for Patients with manic episode.	III	BIPOLAR DISORDER (Manic Episode)	01-jun-01	feb-03	Principal Investigator	CGI-S, CGI-I, YMRS, MADRS
Protocol F1J-MC-HGGY: Placebo-Controled Olanzapine Monotherapy in the Treatment of Bipolar Depression	III	BIPOLAR DISORDER DEPRESSION	01-jul-01	03-Dec-02	Principal Investigator	CGI-S, CGI-I, YMRS, MADRS
Protocol No 062-00: Multicéntric, Double Blind, on Acute Phase and extensión. Controlled with Placebo and active Comparator of two doses of MK-0869 for treatment with Major Depression	II	MAJOR DEPRESSION	01-mar-02	01-mar-03	Principaal Investigator	HAMD-17, CGI-I
Protocol BGU-BC-LRAG: Observational, Multicentric, Prospective, of 1 year on Patients diagnosed for Major Depression	Observational	MAJOR DEPRESSION	20-aug-02	01-mar-04	Principal Investigator	Visual Scale Analogue, HAMD, HAM-A
Protocol No. 5077/9045: Multicentric to describe changes on the weight of schizophrenic or schizoaffective patients with Quetiapine or Olanzapine	IV	SCHIZOPHRENIA AND QUALITY OF LIFE	01-mar-03	jul-04	Principal Investigator	BPRS, GAF
Protocol No.5077/9053: Multicentric to describe Quality Life on schizophrenic patients with Quetiapine or Haloperidol	IV	SCHIZOPHRENIA AND WEIGHT	01-jul-03	oct-04	Principal Investigator	BPRS, GAF



Protocol PEP 001 - Determination of the predictors of the clinical outcome and social and occupational functioning of patients who are diagnosed with a first psychotic episode: A key to the optimization of the prognosis.	Observational	SCHIZOPHRENIA	01-oct-03	2007	Principal Investigator	BPRS,GAF,
Protocol S1543001:A Randomized, Double-Blind, Placebo-Controlled and Risperione-Referenced, Parallel-Group Efficacy and Safety Study of Two Fixed Doses of Bifeprunox in the Treatment of Schizophrenia	III	SCHIZOPHRENIA	01-aug-04	2006	Principal Investigator	MINI, YMRS, MDRAS, CGI-S, SF-36, PSP, ESRS, Resource Use Questionary
Protocol: D1447C00144: Embolden II,Multicenter, randomized, parallel – group, double-blind, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate and lithium as monotherapy for up to 104 weeks, maintenance treatment of Bipolar I disorder in adult patients	III	BIPOLAR DISORDER	01-mar-05	2007	Principal Investigator	YMRS, CGI, MADRS
Protocol S1543002:A Open-label, Flexible-dose, long-term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizophrenia. (Extension of Protocol S1543001)	III	SCHIZOPHRENIA	01-jan-06	2007	Principal Investigator	PANSS, CGI
Protocolo Embolden II D134: multicentre, double-blind, randomized, parallel group, placebo-controlled study of the efficacy and safety of quetiapine fumarate, single oral dose of 300mg or 600mg, and paroxetine, as monotherapy in adult patients with bipolar depression, for 8 weeks , and quetiapine in continuation treatment for 26 to 52 weeks..	IIIb	Bipolar Disorder DEPRESSION	01-jan-06	2007	Principal Investigator	MADRS, CGI-TAB, YMRS
Protocolo: A1281134 Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia	III	SCHIZOPHRENIA IN CHILDREN	18-jul-06	abr-08	Principal Investigator	School Placement Questionary, CHQ, CGAS, BPRS-A, AIMS, BARS, SAS, CNSVital CDRS-R, CPBAQ, Tanner.



Protocolo RIS BMN 3001: Randomized, double-blind, placebo-controlled, active control study of parallel groups, to evaluate the efficacy and safety of long-acting injectable risperidone for the prevention of episodes of changes in mood in the treatment of subjects with bipolar disorder I	III	BIPOLAR DISORDER	17-oct-06	13-may-09	Principal Investigator	YMRS, CGI, MADRS
Protocolo: A1281135 26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia	III	SCHIZOPHRENIA IN CHILDREN	17-oct-06	abr-08	Principal Investigator	School Placement Questionary, CHQ, CGAS, BPRS-A, AIMS, BARS, SAS, CNSVital, CDRS-R, CPBAQ, Tanner.
Mondrian S308.3.002: Double-blind, double-blind, placebo controlled parallel group study of SLV308 as adjuvant treatment of levodopa in patients with Parkinson's disease who experience motor fluctuations.	III	PARKINSON	01-jan-07	2008	Sub Investigator	MMSE, CGI-S, CGI-I, UPDRS Part I-IV, Modified Hoehn & Yahr, Schwab and England, PDQ-39, HADS, Cronic Pain Questionary, Visual Analogue Scale, PGI
Protocol Mondriaan S308.3.007: An extension of the Mondriaan study: Open safety extension of SLV308 from study S308.3.002 in patients with Parkinson's disease who experience motor fluctuations	III	PARKINSON	01-jan-07	2008	Sub Investigator	MMSE, CGI-S, CGI-I, UPDRS Part I-IV, Modified Hoehn & Yahr, Schwab and England, PDQ-39, HADS, Cronic Pain Questionary, Visual Analogue Scale, PGI
Protocol 3151 A1 – 402 WW: Multicenter, 8-Week, Double-blind Randomized, Acute Phase Study, Followed by a Continuation Phase (Open or Double Blind) of Months of Duration to Evaluate the Efficacy, Safety, and Tolerability of DVS SR in Comparison with Escitalopram in Postmenopausal Women with MDD	III	DEPRESSION POST-MENOPAUSAL	01-may-07	27-oct-08	Principal Investigator	HAMD, HAM-A, CGI



Protocol e-Star: Registration of Adherence to the Treatment of Schizophrenia Protocol M100907 / LTE6673 SAMS: Efficiency and Safety of 2 MG / day M100907 in sleep maintenance insomnia with a secondary study of the effect of M100907 on stable type 2 diabetes mellitus: one-year, multicenter, randomized, double-blind study controlled with placebo	IV	SCHIZOPHRENIA	11-jun-07	30-may-10	Principal Investigator	MINI, CGI-S, EEAG, PSP, SAI-E
Protocol M100907/LTE6673 SAMS: Efficiency and Safety of 2 MG / day M100907 in sleep maintenance insomnia with a secondary study of the effect of M100907 on stable type 2 diabetes mellitus: a one-year, multicenter, randomized, double-blind, placebo-controlled study.	III	INSOMNIA PRIMARY	04-jul-07	11-jun-09	Principal Investigator	FOSQ, PGI, HAD, WLQ, Insomnia Severity Index
Protocolo M100907/LTE6672 SAMS 12: Efficacy and Safety of 2 MG / day M100907 in sleep maintenance insomnia with a secondary study of the effect of M100907 on stable type 2 diabetes mellitus: a 12-week multicenter, randomized, double-blind, placebo-controlled study.	III	INSOMNIA PRIMARY	13-sep-07	11-feb-09	Principal Investigator	FOSQ, PGI, HAD, WLQ, Insomnia Severity Index
Protocol D1050233: Phase 3 Randomized, Double Blind Controlled with Placebo and Active Comparator Trial to Study the Efficacy and Safety of two doses of Lurasidone in Acute Psychotic Subjects with Schizophrenia (PEARL 3).	III	SCHIZOPHRENIA	12-feb-08	12-oct-10	Principal Investigator	PANSS, CGI-S, MDRAS, UCSD-UPSA, Negative Symptom Assessment Scale, Epworth Sleepness Scale, QWB, MSQ, MINI PLUS, SAS, BARS, AIMS,
Protocol R076477-SCH-4013: Study of blind start of satisfaction with medication in subjects with schizophrenia, treated with prolonged-release paliperidone (LP) after a sub optimal response to oral risperidone.	IV	SCHIZOPHRENIA	01-apr-08	01-oct-08	Principal Investigator	PANSS, CGI, AIMS, BARS, SAS
Protocolo R076477-SCH-3017: An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia	IV	SCHIZOPHRENIA	01-apr-08	01-oct-08	Principal Investigator	PANSS, CGI, AIMS, BARS, SAS



Protocol D1050234: Phase 3 Randomized, Double Blind Controlled with Placebo and Active Comparator Trial to Study the Efficacy and Safety of two doses of Lurasidone in Acute Psychotic Subjects with Schizophrenia (PEARL 3).	III	SCHIZOPHRENIA	16-sep-08	19-aug-11	Principal Investigator	PANSS, CGI-S, MDRAS, SAS, AIMS, BARS, UCSD-UPSA, Negative Symptoms Assessment Scale, Epworth Sleepness Scale, QWB, Intent to Attend Assesment
Protocolo D1050231: Phase 3 Randomized Clinical Trial, Controlled with Placebo and Active Comparator to Study the Safety and Efficacy of Two Doses of Lurasidone HCL in Acute Psychotic Patients with Schizophrenia	III	SCHIZOPHRENIA	28-oct-08	05-apr-10	Principal Investigator	MINI, BAS,AIMS, SAS, PANSS, CGI-S, MDRAS
Protocol 12473A: Multicenter, randomized, placebo-controlled, double-blind, relapse prevention study with Lu AA21004 in patients with generalized ANXIETY disorders (GAD)	III	ANXIETY	15-jan-09	19-jul-10	Principal Investigator	MINI, HAM-A, MDRAS, CGI-S, CGI-I, HAD, SF-36, SDS, HEA, C-SRSS
Protocol ESTIGMA: Study Stigma, social discrimination and functional phase I in bipolar patients from Argentina, Brazil, Mexico, Colombia	N-A	BIPOLAR DISORDER	01-feb-09	30-apr-11	Principal Investigator	HAMD, YMRS, FAST
Protocolo Merck Serono 27918: A phase III, double blind, placebo controled randomised trial to determinate the efficacy and safety of a low (50mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson's Disease treated with stable dose of a single dopamine agonist.	III	PARKINSON	21-apr-09	03-sep-12	Sub Investigator	MMSE, UPDRS Section I-IV, CGI-S, GRID-HAMD, PDQ-39, EQ-5D, HRU, COGTEST, Epworth Sleepness Scale, PGI-C, QUIP



<p>Protocolo D1443L00055: A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination with Lithium in the Treatment of Patients with Acute Bipolar Depression. Version 2 date 16 December 2008</p>	IIIb	BIPOLAR DISORDER DEPRESSION	01-jul-09	30-jun-11	Principal Investigator	HAMD, MDRAS, YMRS, HAM-A, CGI-S, CGI-I
<p>Protocol D144AC00001: An 8-week, multicenter, double-blind, randomized, parallel-group, placebo-controlled study of the efficacy and safety of quetiapine fumarate (SEROQUEL®) prolonged-release in subjects, children and adolescents, with bipolar depression.</p>	III	BIPOLAR DISORDER DEPRESSION CHILDREN	15-jul-09	31-mar-11	Principal Investigator	K-SADS-PL, CDRS-R, YMRS, CGI-BP-S, SAS, AIMS, BARS, C-SRSS, CGI-BP-C
<p>Protocol DVS SR 3151A1-3360-WW: Multicenter, randomized, double-blind, placebo-controlled, randomized, parallel group study to evaluate the efficacy and safety of 50 mg / day of DVS SR in adult outpatients with major depressive disorder. 3151A1-3360-WW</p>	III	MAJOR DEPRESSION	23-sep-09	01-Oct 2011	Principal Investigator	MINI, C-SSRS, HAMD, CGI-S, CGI-I, WPAI, WHO-5
<p>Protocolo R092670-SCH-3004rospective, randomized, active-controlled, blind-scale, relapse prevention evaluator comparing paliperidone palmitate with oral risperidone in recently diagnosed adult patients with schizophrenia who are at high risk of relapse.</p>	IIIb	SCHIZOPHRENIA	30-oct-09	05-mar-10	Principal Investigator	SCID, PANSS, CGI-S, NSA-4, COVI, PSP, Health Outcome Evaluation, MSQ, ASEX, ISST-PLUS, ESRS-A,
<p>Protocol SAM-531 3193A1-2005-WW: A 52-week, 2-period, multicenter, randomized, double-blind, placebo-controlled, donepezil-linked trial of efficacy and safety to compare three dose levels of SAM 531 in outpatients with mild to moderate Alzheimer's disease.</p>	IIb	ALZHEIMER'S DISEASE	24-nov-09	09-dic-11	Principal Investigator	NINCDS-ADRDA, CSDD, HACHINKSI ISCHEMI, MMSE, ADAS COG, DAD, ADCS-CGIC, MPI, CANTAB, QoL-AD, SDI, Dependence Scale
<p>Protocol MK 4305-009: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia</p>	III	INSOMNIA PRIMARY	28-jan-10	20-sep-11	Principal Investigator	MINI, C-SSRS, QIDS-SR16, MMSE, CGI-S, CGI-I, PGI-S, PGI-I, ISI, MCQ, Tyrer Questionary





Psychometric Validation Study Protocol MATRICS: Development of the Standardization of the group of tests to measure Memory and Attention.	N-A	HEALTHY SUBJECTS	22-feb-10	01-jan-11	Principal Investigator	MATRICS
Protocolo D4130C00005: A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase III study on the efficacy and safety of 3 fixed-dose groups of TC-5214 (S-mecamylamine) as adjuvant of an antidepressant in patients with depressive disorder Severe who show an inadequate response to antidepressant therapy.	III	DEPRESSION MAJOR	09-feb-11	01-mar-12	Principal Investigator	MINI, QIDS-SR-16, SDS, Q-LES-Q-SF, CSFQ, EQ-5D, HAM-A, HAMD-17, MDRAS, CGI-S, CGI-I, C-SSRS, BARS, AIMS, BARS, DESS
Protocol RGH-MD-05 Double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in the acute exacerbation of Schizophrenia	III	Schizophrenia	17-feb-11	26-apr-12	Principal Investigator	SCID, SCI-PANSS, CGI-S, NSA-16, CGI-I, SAS, AIMS, BARS, C-SSRS, SCLSR-4, CDR - CTT
Local Schizophrenia Protocol: Outcome study of patients with recently diagnosed schizophrenia.	III	Schizophrenia	01-mar-11	01-Dec-17	Principal Investigator	MINI, CGI, GAF, PSP, SAI-E
Protocol D1050292 A Randomized, 6 week, double-blind, placebo-controlled, flexible-dose, parallel-group study of Lurasidone adjunctive to lithium or divalproex for the treatment of Bipolar I Depresión in Subjects demonstrating non-response to treatment with lithium or divalproex alone	III	DEPRESSION Bipolar I	09-aug-11	20-sep-11	Principal Investigator	MINI, BPI, MDRAS, C-SRSS, HAM-A, YRMS, SDS, Q-LES-Q-SF, MSQ, AIMS, BARS, SAS, CGI-BP-S, Intent to Attend Assessment, QIDS-SR
Protocol D1050256 Extension study of 24 weeks, open label and flexible dose of Lurasidone for the treatment of Bipolar Depression I	III	DEPRESSION Bipolar I	09-ago-11	04-abr-13	Principal Investigator	MADRS, C-SRSS, HAM-A, YMRS, SDS, Q-LES-Q-SF, AIMS, BARS, SAS, CGI-BP-S.
Protocol 331-10-230. A phase 3, multicenter, randomized, double-blind, placebo controlled trial of fixed-dose OPC-34712 (4,2 and 1 mg/day) in the treatment of adults with acute schizophrenia.	III	Schizophrenia	15-feb-12	27-feb-14	Sub Investigator	MINI, BPRS, PANSS, CGI-S, CGI-I, PSP, SAS, AIMS, BARS, C-SSRS.



310-10-237: A long- term, Phase 3, Multicenter, open label trial to evaluate the safety and tolerability of oral OPC-34712 as maintenance treatment in adults with schizophrenia.	III	Schizophrenia	28-mar-12	04-apr-16	Sub Investigator	PANSS, CGI-S, CGI-I, PSP, SAS, DIEPSS, AIMS, BARS, C-SRSS, RUF
Protocol PO5896 An 8-week placebo-controlled, double-blind, randomized, fixed-dose study to assess the efficacy and safety of asenapine in adolescent subjects with schizophrenia	III	Schizophrenia in CHILDREN	29-mar-12	02-may-13	Principal Investigator	TANNER, K-SADS-PL, CGAS, PANSS, CGI-S, C-SSRS, ESRS, CDRS, PQ-LES-Q, CGI-I.
Protocol PO5897 Multicenter, open-label, 26-week study of flexible dose of long-term safety on asenapine in adolescent subjects with schizophrenia	III	Schizophrenia in CHILDREN	29-mar-12	02-may-13	Principal Investigator	TANNER, CGAS, PANSS, CGI-S, C-SSRS, ESRS, CDRS, PQ-LES-Q, CGI-I.
Protocol PO5664 Phase 3, Double Blind, Double Simulation, Placebo controlled and Active Treatment, to determine the dose range, Efficacy and Safety of Preladenant in patients with Early Parkinson's Disease	III	Parkinson	29-mar-11	09-sep-13	Sub Investigator	QUIP-RS, MoCA, BDI-II, Epworth Sleepness Scale, EQ-5D, PDQUALIF, SAQ, C-SRSS, UPDRS
RGH-MD-11 Evaluation of the long-term safety and tolerability and pharmacokinetics of cariprazine in patients with schizophrenia.	III	Schizophrenia	11-apr-11	20-feb-13	Principal Investigator	SCID, SCI-PANSS, CGI-S, C-SSRS, BAR, AIMS, SAS, SQLS-R4, CDR-CTT
Protocol NN25310: A Phase III, multi center, randomized, 24week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838in stable patients with predominant, persistent negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.	III	Schizophrenia	31-may-12	06-aug-14	Sub Investigator	C-SSRS, ESRS-A, SCID - CT, CDSS, PANSS, CGI-S, NSA-16, MCCB, CGI-I, PSP, WoRQ, EQ-5D, S-MRU, ZBI



Protocol NN25307 A Phase III, multi-center, 12 week, double-blind, randomized multicenter, 12-week, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo- controlled treatment period.	III	Schizophrenia	31-may-12	23-sep-14	Sub Investigator	ESRS-A, C-SRSS, SCID-CT, PANSS, CGI-S, CGI-I, PSP, WoRQ, EQ-5D, S/MRU, ZBI
Protocol R092670-SCH3012 Open, Prospective Study to explore the Tolerability, Safety and Efficacy of Paliperidone Palmitate in Flexible Doses in Subjects with Schizophrenia.	III	Schizophrenia	31-jul-12	20-dec-13	Sub Investigator	MINI, PANSS, CGI-S, PSP, MSQ, RDQ, AIMS, ISST-PLUS
Protocolo MEM-MD-91 Open study to evaluate the safety and tolerability of memantine in pediatric patients with Autism, Asperger's Syndrome, or pervasive developmental disorders not specified	III	AUTISM in CHILDREN	03-dec-12	04-sep-13	Sub Investigator	KBIT-2, ADI-R, ADOS, SRS, CCC-2, CGI-S, CGI-I, Aberrant behavior check list community, Suicidality Assessment ABC-I (Irritability Subscale), C-SSRS
Protocol RGH-MD-56 Double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar depression	Iib	Bipolar Disorder DEPRESSION	20-dec-12	01-jan-14	Principal Investigator	HAMD-17, SCID, MDRAS, YMRS, CGI-S, FAST, BAR, AIMS, SAS, C-SRSS
Protocol R092670-PSY 3012: A randomized, Multicenter, double-blind, relapse prevention study of Paliperidone Palmitate 3M formulation for the treatment of subjects with schizophrenia.	III	Schizophrenia	03-jan-13	24-jul-14	Sub Investigator	PANSS, CGI-S, PSP, MPQ, Involvement Evaluation Questionary, SF12, HRUQ, AIMS, BARS, SAS, C-SRSS
Protocolo D1050298 Continuous, long-term, multicenter, open-label study, with flexible doses, in subjects who have completed a previous study of lurasidone	III	DEPRESSION Bipolar I	10-jan-13	17-jul-14	Principal Investigator	CGI-S, C-SRSS, AIMS, BARS, SAS



PROTOCOL TAK-375SL_203: A randomized, double-blind, placebo-controlled, Study of Phase 3 to evaluate the efficacy and safety of once day, TAK-375SL 0.1, 0.4 and 0.8 mg as adjunctive therapy to treatment –as- usual in the maintenance treatment of bipolar 1 disorder in adult subjects.	III	Bipolar Disorder DEPRESSION	28-feb-13	10-aug-15	Principal Investigator	MADRS, BPI, SCID, YMRS, HAM-A, CGI-S, Q-LES-Q, CTSSM, C-SRSS
Protocol TAK-375SL_201: A randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of once a day TAK-375 (ramelteon) . Tablet for sublingual administration (TAK-375SL Tablet) 0.1, 0.4 and 0.8 mg as an adjunctive therapy in the treatment of acute depressive episodes associated with bipolar I disorder in adults subjects.	III	Bipolar Disorder DEPRESSION	28-feb-13	30-jul-15	Principal Investigator	BPI, SCID, MADRS, YMRS, HAM-A, CGI-S, CGI-I, SDS, QIDS-SR, RSQ-W, Q-LES-Q-SF, CTSS-M, SCQ, C-SRSS
331-10-232: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety and tolerability of Brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia.	III	Schizophrenia	07-mar-13	19-mar-15	Sub Investigator	MINI, PANSS, CGI-S, GAF, PSP, SAS, AIMS, BARS, C-SRSS.
Protocol MEM-MD-69 Open study to evaluate the safety and tolerability of memantine in pediatric patients with Autism, Asperger's Syndrome, or pervasive developmental disorders not specified	III	AUTISM in CHILDREN	18-apr-13	30-apr-14	Sub Investigator	CRS, CCC2, CGI-S, CGI-I, ABC-C, Suicidality Assessment, KBIT-2
Protocol MEM-MD-68 Open study to evaluate the safety and tolerability of memantine in pediatric patients with Autism, Asperger's Syndrome, or pervasive developmental disorders not specified	III	AUTISM in CHILDREN	18-apr-13	22-oct-13	Sub Investigator	KBIT-2, CCC-2, CGI-S, CGI-I, Aberrant behavior check list community, C-SSRS
Protocol D1050303:A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of low dose lurasidone in the acutely psychotic subjects with schizophrenia.	III	Schizophrenia	05-sep-13	24-sep-14	Principal Investigator	SCID-CT, PANSS, MDRAS, BARS, SAS, AIMS, GAF, CGI-S, CGAS, EQ-5D, MSQ, C-SRSS, Intent to attend



<p>Protocol EVP-6124-016: A randomized, double-blind, placebo-controlled, parallel, 26 week, phase 3 study of 2 doses of an alpha-7 nivotinic acetilchiline receptor agonist (EVP-6124) or placebo as an adjunctive pro-cognitive treatment in schizophrenia subjects on chronic stable atypical antipsychotic therapy</p>	III	Schizophrenia	20-nov-13	06-apr-16	Principal Investigator	SCID, BPRS, CDSS, C-SRSS, SAS, CGI-S, CGI-C, PANSS, EQ-5D
<p>D1050301: A 6 week randomized, parallel, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of Lurasidone in adolescent subjects with schizophrenia</p>	III	Schizophrenia	10-jul-14	29-mar-16	Principal Investigator	K-SADS-PL, TANNER, BARS, SAS, AIMS, PANSS, CGI-S, CGAS, PQ-LES-Q, C-SRSS, UKU
<p>EVP-6124-017: A multicenter 26 week extension study to evaluate safety and clinical effect of prolonged exposure to 1 and 2 mg doses of EVP 6124, and Alpha-7 nicotinic acetylcholine receptor agonist, as an adjunctive pro-cognitive treatment in subjects with schizophrenia on chronic stable atypical antipsychotics therapy.</p>	III	Schizophrenia	25-sep-14	07-apr-16	Principal Investigator	CDSS, C-SRSS, SAS, CGI-S, CGI-C, EQ-5D-5L
<p>Protocol D1050326: A randomized, 6-week, double-blind, placebo-controlled, flexible-dose, parallel group study to evaluate the efficacy and safety of lurasidone in children and adolescent subjects with bipolar I depression.</p>	III	BIPOLAR DISORDER	17-mar-15	12-dec-16	Principal Investigator	K-SADS-PL, TANNER, BARS, SAS, AIMS, CDRS-R, CGI-BP-S, CGAS, YMRS, PQ-LES-Q, C-SRSS, UKU, PARS, ADHD-RS
<p>Protocol D1050302: A 104-week, flexible-dose, open label, multicenter, extension study to evaluate the long-term safety and effectiveness of lurasidone in Pediatric subjects.</p>	III	Schizophrenia	20-nov-14	12-dec-18	Principal Investigator	TANNER, BARS, SAS, AIMS, PANSS, CGI-S, CGAS, PQ-LES-Q, C-SRSS, UKU



12709A Randomized, double-blind, placebo-controlled, active-reference (fluoxetine) and fixed-dose study of Vortioxetine in pediatric patients aged 7 to 11 years with major depressive disorder (MDD).	III	TDM	02-Aug-17	Open	Principal Investigator	K-SADS-PL, BPI, CDRS-R, CGI-S, CGI-I, PGA, GBI, CGAS, PedsQL VAS(PRO), PQ-LES-Q (PRO), TANNER, PAERS, C-SRSS, GBI,
Effect of Paliperidone palmitate in the use of hospital resources in patients diagnosed with schizophrenia in Colombia	Observational	Schizophrenia	27-Sep-17	31-dic-19	Project Director	MINI, CGI-SCH, C-SSRS, P GAF, WHODAS, EQ-5D, Zarit Burden, EURS, BARS, SAS, AIMS
12712A Long-term, open-label, flexible-dose, extensión study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age.	III	TDM	12-Dec-17	Open	Principal Investigator	K-SADS-PL, BPI, CDRS-R, CGI-S, CGI-I, PGA, GBI, CGAS, PedsQL VAS(PRO), PQ-LES-Q (PRO), TANNER, PAERS, C-SRSS, GBI,
Treatment Resistant Depression in America Latina. TRAL Study	Observational	TDM	15-mar-18	Open	Principal Investigator	MINI, MADRS, C-SSRS, PHQ9, EQ-5D-5L, SDS, WPAI
ACP-103-046 Multicenter, Randomized, Double-blind, placebo-controlled, safety, study of Primavanserin Therapy in Adult and Elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease	III	Neurodegenerative disease	15-aug-19	Open	Principal Investigator	MMSE, NPI, CGI-S, CGI-I, C-SSRS, GCAS, ESRS-A, EQ-5D-5L, SDI.
ACP-103-047. Estudio abierto de extensión de 52 semanas con Pimavanserina en pacientes adultos y ancianos con síntomas neuropsiquiátricos relacionados con enfermedad neurodegenerativa	III	Enfermedad Neurodegenerativa	15-ago-19	Open	Principal Investigator	MMSE, NPI, CGI-S, CGI-I, C-SSRS, GCAS, ESRS-A, EQ-5D-5L, SDI.

**PUBLICATIONS**

Documents	Name of publication	Year	Registry ISSN/ ISBN
Economic evaluation of Paliperidone Palmitate use in patients with schizophrenia in the maintenance phase (post relapse or stabilization) in Colombia	Value in Health	2016	A1 - A 318
Clinical Outcomes in Schizophrenia Patients During First Years of Diagnosis, a Cohort Study. Artículo en Revista Indexada Internacionalmente	CNS Spectrum	2015	1092-8529
Textbook published by Ediiiveramerica. Modified version for Colombia Grupo Cisne Ltda.	DSM 5 ¿QUO VADIS?	2013	978-84-15734-02-4
Textbook published by medical classroom editorial. Modified version for Colombia Grupo Cisne Ltda ..	Lo que siempre quiso saber de los psicofármacos...y nunca se atrevió a preguntar	2013	978-84-7885-540-7
Electronic record of adherence to the treatment of Schizophrenia in Latin America (e-Star) Article in specialized magazine indexed internationally.	Salud Mental	2013	0185-3325
A randomized, double –blind placebo – controlled trial to asses prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Artículo en revista especializada indexada internacionalmente.	Euopean Neuropsychopharmacology	2012	0012-6667
Study of flexible doses of paliperidone with schizophrenia previously treated without effectiveness with other antipsychotics. Article in specialized magazine indexed internationally.	Revista Colombiana De Psiquiatría	2012	0034-7450
Journal of Affective Disorders. . Article in specialized magazine indexed internationally.	Journal Of Affective Disorders	2011	0165-0327
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow – up from the electronic Schizophrenia treatment adherence registry in Latin America. Artículo en revista especializada indexada internacionalmente.	Neuropsychiatric Disease And Treatment	2011	1176-6328
Current clinical advances and future perspectives in the psychiatry/mental health field of Latin America. Artículo en revista especializada indexada internacionalmente.	International Review Of Psychiatry	2010	0954-0261
Text guide published by Ars medica. Modified version for Colombia Grupo Cisne Ltda	¿Qué sabemos de la esquizofrenia? Guía para pacientes y familiares	2009	84-9706-059-8
The Latin American psychiatric doctor: his profile and his degree of satisfaction with the specialty. Article in specialized magazine indexed internationally.	Actas Españolas De Psiquiatría	2009	1139-9287
Factors that determine the severity of clinical presentation of the first psychotic episode. Article in specialized magazine indexed	Revista Salud Pública	2007	0124-0064

VERSION DATE  
FEBRUARY 2020



internationally..			
Factors that determine the severity of clinical presentation of the first psychotic episode. Article in specialized magazine indexed internationally.	Revista Colombiana De Psiquiatría	2007	0034-7450
Trends of suicide in Colombia, 1985-2002. . Article in specialized magazine indexed internationally.	Revista Panamericana De Salud Publica	2007	1020-4989
Latin American psychiatrics profile. . Article in specialized magazine indexed internationally.	Worl Journal of biological Psychiatric supplement	2007	
Repetitive transcranial magnetic stimulation in a patient with chronic bilateral tinnitus. . Article in specialized magazine indexed internationally..	Revista De Neurología	2006	0210-0010
Textbook published by Modified version for Colombia	Detección temprana de enfermedades mentales y manejo de trastornos mentales	2006	958-33-9340-1

### WORKS IN EVENTS

Event	Name	Institution	Date
Speaker 3th International Congress of Dual Patology	Early Signals of Bipolar Disorder	El Bosque University	16 Mar 2018
Conference VII Symposium of Liaison Psychiatry	"Liaison Psychiatry Symposium"	Fundation Santa Fe de Bogotá	24 Nov 2017
Speaker at the XX National Congress of Psychiatry of Barcelona	Suicide	Spanish Society of Psychiatry / APAL / WPA	16-18 Nov 2017
Speaker X Uruguayan Congress of Psychiatry III regional meeting of Residents and Psychiatrists in training	"Psychiatry and mental health. Facing the stigma "	Uruguayan Society of Psychiatry WPA	19-21 Oct 2017
Speaker WPA XVII World Congress Of Psychiatry	Prevention in Schizofrenia	WPA APA American Psychiatric Association Berlin - Germany	8-12 Oct 2017
Speaker III Symposium of Schizophrenia Program of UNIFESP	Management and treatment of Psychosis	Paulista Center of Studies of Psychiatry Sao Paulo	22-23Sept 2017
1st Forum Conferneclist Innovation Forum on Severe Mental Illness in Colombia	Integrated services networks	Colombian Association of Psychiatry	11 Aug 2017
Conference Center for Research and Training ACEMI	Policy for the Colombian health system	Colombian Association of Integral Medicine companies	12 Jul 2017

VERSION DATE  
FEBRUARY 2020





Speaker Congress Post Apa Mexico	Schizophrenia and other Psychosis	Mexican Association of Psychiatry Mexico City	07 Jul 2017
Speaker orientation school	"Mental health and risk factors"	Alcaldia Mayor de Bogota D.C	02 Jul 2017
Conference Annual meeting American Psychiatric Association	Meeting Annual	American Psychiatric association San Diego	20-24 May 2017
Speaker Symposium on Oncohematology evolution	Liaison psychiatry - moods and affection	Colombian Association of Hematology and Oncology Cartagena	05-06 May 2017
Speaker Workshop on psychomotor agitation and Adasuve	Psychomotor agitation in psychosis	Association of Psychiatry of Latin America Mar de la Plata-Argentina	27- Apr-2017
Conference XXXII Argentina Congress of Psychiatry	"New challenges in mental health"	APSA – Argentina	26-29 Apr-2017
Speaker XVIII National Conference of Dual Pathology	Addiction and other mental disorders	Spanish Society of Dual Pathology	14-16 Apr-2017
Speaker Latin American regional meeting of the World Association of Psychiatry	Bipolar Disorder	Ecuadorian Association of Psychiatry	8-11 Feb 2017
Speaker XXXIV Brazilian Congress of Psychiatry	Comprehensive care of the patient with affective disorder	Brazilian Association of Psychiatry Sao Paulo	16-19 Nov 2016
Conference International Course Excellence Management in chronic diseases	Chronic diseases	Research and Training Center ACEMI	10-11 Nov 2016
Speaker 1 st Regional Seminar on the Coffee Region of Mental Health	First psychological help in the framework of the commemoration of World Mental Health Day.	Metropolitan Convention Center Armenia - Quindio	08-Nov-2016
Speaker XXIX Latin American Congress of Psychiatry Guatemala	Depression	Psychiatry Association Latin America Antigua Guatemala	29 Oct 1 Nov 2016
Speaker XIX National Congress of Psychiatry Madrid - Spain	New Psychotropic drugs in psychosis	Spanish Society of Psychiatry	27-29 Oct-2016
Speaker Latin American Congress	Controversies in diagnosis	APAL Psychiatric Association of Latin America	22-25 Aug-2016



Conference in the VIII Cuban Congress of Psychiatry	Risk Factors in Bipolar Disorder	Cuban Society of Psychiatry	19-23 Oct 2015
Conference at the XVIII National Congress of Psychiatry Santiago de Compostela	Position of the APAL, before the stigma in Psychiatry	Spanish Society of Psychiatry / APAL / WPA	26 sep 2015
Speaker at the XXIII Peruvian Congress of Psychiatry	First Episode of Psychosis	Psychiatric Association Peru	27-29 Aug 2015
Speaker at the XXIII Peruvian Congress of Psychiatry	Mental Health and Reform	Psychiatric Association Peru	27-29 Aug 2015
Speaker at the 3rd International Congress of Clinical Psychology and Psychopharmacology. 5th Argentine Congress	New Perspectives in Affective and Non Affective Psychosis. Pródromos and First Episodes Psicóticos	Fundación CEDES / Hospital Escuela Dr. Carlos Pereyra / Hospital salud Mental / Argentina	Nov-14
Paper not published in a specialized academic event.	Impact of Injectable Risperidone for Prolonged Action in the Frequency of Hospitalization of Patients with Schizophrenia	Janssen	nov-14
Paper not published in a specialized academic event.	Efficacy of Prolonged Action Risperidone in Patients with Schizophrenia	Janssen	feb-14
Paper not published in a specialized academic event.	Cost-Benefit Análisis Of Four Antipsychotic Drugs For The Treatment Of Schizophrenia In Colombia	Janssen	sep-12
Paper not published in a specialized academic event.	Clinical Outcomes In Schizophrenia Patients During First Years Of Diagnosis, A Cohort Study	Centro De Investigación Del Sistema Nervioso	sep-12
Paper not published in a specialized academic event.	Use of Hospital Resources in Patients with Schizophrenia Before and After Treatment with an Atypical, Long-acting, Injectable Antipsychotic	Paper Not Published in Specialized Academic Event	nov-11
Paper not published in a specialized academic event.	Randomized, Double-Blind, Placebo-Controlled Study Of Risperidone Long-Acting Injectable In Relapse Prevention In Patients With Bipolar I Disorder	Supported By Funding From Johnson Y Johnson Pharmaceutical Research Y Development	feb-10
Paper not published in a specialized academic event.	Clinical Results of a Two-Year Follow-up Study of Patients with Diagnosis of Schizophrenia Treated with Prolonged Injectable Risperidone	Janssen	nov-08



Paper not published in a specialized academic event.	Clinical Outcomes in Patients with Schizophrenia in the First Years of Evolution cohort study	Centro De Investigación Del Sistema Nervioso	sep-07
Paper not published in a specialized academic event.	Study of Flexible Doses of Paliperidone to Patients with Schizophrenia Previously Treated Previously Treated with Other Atipsicotics	Janssen	feb-06
Paper not published in a specialized academic event.	Substance Abusa In First Episode Pscynosis In Colombia	Centro De Investigación Del Sistema Nervioso	feb-06

**OTHERS**

<b>National Awards</b>	Recognition for their great contribution to the configuration and implementation of our organization	Colombian Council of Accreditation and Medical Recertification, of Specialists and Related Professionals CAMEC	8 Apr 2014
<b>International Awards</b>	Recognition for valuable academic contribution that made possible the successful realization of scientific events	Venezuelan School of Neuropsychopharmacology	15 Jul 2004
<b>International Awards</b>	Recognition for his participation as Professor in the Schizophrenia Consensus of the APAL and the WPA & National Forum of Schizophrenia of the Mexican Psychiatric Association and the Academic-Scientific Meeting of the Schizophrenia Clinic of the Fray Bernardino Álvarez Psychiatric Hospital	APAL and the WPA & National Forum of Schizophrenia of the Mexican Psychiatric Association and the Academic-Scientific Meeting of the Schizophrenia Clinic of the Fray Bernardino Álvarez Psychiatric Hospital	18-20 Mar 2004
<b>International Awards</b>	Honorable Mention as President of ACP	Colombian Association of Psychiatry	15 Oct 2000
<b>Memberships</b>	<b>Institution</b>	<b>Start Date</b>	<b>End Date</b>
President	Psychiatric Association of Latin America	2014	2016
Vice President		2012	2014
Regional Secretary		2004	2004
Full Member		1991	Nowdays
Member of the Health Advisory Board	National Health Association Board	April 2015	Nowdays
Internatinal Member	American Psychiatric Association	Mar 2008	Nowdays
Vice President of Social Communication	Colombian Medical Association	May 2003	Nowdays
Treasurer	Colombian Association of Scientific Societies	2014	2016
President		2010	2012
Vice president		2008	2010



President Honorary member	Colombian Association of Psychiatry	1999 15 Oct 2000	2000 Nowdays
Honorary Member of the Scientific Committee	Colombian Association of Patients with Schizophrenia	2 Sep 2000	Nowdays
Full Member and part of: Executive Committee, Scientific Committee	World Association of Psychiatry	Oct 2003 Oct 1999, 2008, 2011, 2013 1991	Nowdays
Member	Association of Rosaristas Doctors	10 Nov. 1995	Nowdays
Member	Association of early psychosis	2003	Nowdays

**OTHERS**

**GCP training-** Amendment E6 R2 ICH GCP; Resolution 2003 of 2014; HELSINKI DECLARATION (64th Fort General Assembly, Brazil, October 2013; External Circular SMPB-600-464-12 AES Report October 4, 2012; Resolution No, 2011020764 June 2011; Resolution 2378 of 2008; 1999; Resolution 3823 of 1997, Resolution 8430 of 1993. February 9, 2018.

**GCP - ICH, HELSINKI and Regulatory Affairs Training.** 64 th,WMA General Assembly, **Fortaleza**, Brazil, october, 2013); Resolution 8430, 1993; Resolution 3823, 1997; Resolution 1995, 1999; Resolution 2378, 2008; Resolution No, 2011020764, June 2011, Resolution 1441, 2013. February 19, 2016.

**GCP -** Amendment E6 R2 ICH GCP February 2017; Resolution 2003 of 2014; HELSINKI DECLARATION (64th Fort General Assembly, Brazil, October 2013; External Circular SMPB-600-464-12 AES Report October 4, 2012; Resolution No, 2011020764 June 2011; Resolution 2378 of 2008; 1999; Resolution 3823 of 1997, Resolution 8430 of 1993. February 9, 2018

**Languages proficiency**

Vancouver English Centre  
Canada- British Columbia  
One week Private Tutoring Program & One week Super Intensive Program in a English as a Second Language  
13-Mayo2008  
English Reading (Good), Writing (Good), Listening (Good), Conversation (Acceptable)

Sing

Date

	07- FEB-2020
--	--------------